PharmaWatch: Updates Impacting the Workers’ Compensation Industry

On July 16, 2024, Endo USA, Inc. voluntarily recalled a single lot of Clonazepam 0.125 mg and 0.25 mg Orally Disintegrating tablets (ODT) due to a packaging error.

Effective July 26, 2024, ODG by MCG is updating Appendix A − its drug formulary – with the following medication edits to both the preferred, first-line “Y” drugs, and drugs that are not recommended as a first-line treatment known as “N” drugs.

Read our new Q2 2024 (January through March) pipeline report that features new drug approvals, new generics, withdrawals and discontinuations of certain products, as well as near-term pipeline products and patent expirations.

On June 13, 2024, Collegium Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for opioid medications Nucynta® and Nucynta® ER.

The Georgia Board of Workers’ Compensation (BWC) recently released its updated medical fee schedule guidelines and rules for the coding and reimbursement of topical medications.

On June 13, 2024, the California Department of Industrial Relations, Division of Workers’ Compensation (DWC) published amended proposed rule changes to the Physician and Non-Physician Practitioner and Pharmaceutical Fee Schedules. These changes will add to costs for both program administration and the delivery pharmacy services.